High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases (Q43726094)

26 November 2017

title

High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases (English)

1 reference

26 November 2017

0 references

1 reference

A L Zackrisson

1

1 reference

26 November 2017

B Lindblom

series ordinal

2

1 reference

26 November 2017

J Ahlner

series ordinal

3

1 reference

26 November 2017

language of work or name

English

0 references

publication date

11 November 2009

1 reference

Clinical Pharmacology & Therapeutics

26 November 2017

published in

1 reference

26 November 2017

volume

88

1 reference

26 November 2017

issue

3

1 reference

26 November 2017

page(s)

354-359

1 reference

Cause of death and drug use pattern in deceased drug addicts in Sweden, 2002-2003.

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Fatal intoxication cases: cytochrome P450 2D6 and 2C19 genotype distributions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Relationship between Type A and B personality and debrisoquine hydroxylation capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Association between cytochrome P450 2D6 genotype and harm avoidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Cytochrome P450 2D6 polymorphism and character traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Relationship between personality and debrisoquine hydroxylation capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

7 January 2021

Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

7 January 2021

Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

7 January 2021

Drug-Metabolizing Enzymes and Therapeutic Drug Monitoring in Psychiatry

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

7 January 2021

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

7 January 2021

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

7 January 2021

Debrisoquine hydroxylation polymorphism and personality

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

7 January 2021

Association of CYP2D6 Genotypes and Personality Traits in Healthy Individuals

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

7 January 2021

Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

7 January 2021

Determination of CYP2D6 gene copy number by pyrosequencing

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.216

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.216

1 reference

Dimensions Publication ID

26 November 2017

1049525347

0 references

1 reference